TEVA Pharmaceutical Industries (TEVA) revenue: $17.3B
TEVA Pharmaceutical Industries reported $17.3B of revenue for the year ended Dec 31, 2025, up 4.3% from $16.5B a year earlier.
From TEVA Pharmaceutical Industries's filings with the SEC · Read the filing · TEVA stock page
TEVA Pharmaceutical Industries revenue by year
#269 of 3,623 US companies by revenue · See the full ranking
| Year ended | Revenue | Change |
|---|---|---|
| Dec 31, 2025 | $17.3B | +4% |
| Dec 31, 2024 | $16.5B | +4% |
| Dec 31, 2023 | $15.8B | +6% |
| Dec 31, 2022 | $14.9B | -6% |
| Dec 31, 2021 | $15.9B | – |
Revenue of similar companies
Companies in the same industry as TEVA Pharmaceutical Industries, by SEC industry code, with the closest revenue. Each name opens the same page for that company.
| Company | Revenue, latest year | Year ended |
|---|---|---|
| Abbott Laboratories | $44.3B | Dec 31, 2025 |
| TEVA Pharmaceutical Industries | $17.3B | Dec 31, 2025 |
| Regeneron Pharmaceuticals | $14.3B | Dec 31, 2025 |
| Viatris | $14.3B | Dec 31, 2025 |
| Vertex Pharmaceuticals Inc / Ma | $12B | Dec 31, 2025 |
| Bausch Health Companies | $10.3B | Dec 31, 2025 |
| Zoetis | $9.5B | Dec 31, 2025 |
Questions and answers
What is TEVA Pharmaceutical Industries's revenue?
TEVA Pharmaceutical Industries reported $17.3B of revenue for the year ended Dec 31, 2025, up 4.3% from $16.5B a year earlier.
Numbers as reported in TEVA Pharmaceutical Industries's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology